The effects of bethanechol and cisapride on urodynamic parameters in patients undergoing radical hysterectomy for cervical cancer. A randomized, double-blind, placebo-controlled study.
To evaluate the effects of bethanechol and cisapride on urodynamic parameters in patients undergoing radical hysterectomy for cervical cancer. In this double-blind, placebo-controlled study, 79 patients with cervical cancer were randomized to receive bethanechol (30 mg/day), cisapride (30 mg/day), bethanechol combined with cisapride (same doses) and placebo. Urodynamic study was performed, including flowmetry, cystometry, pressure-flow study and urethral pressure profile before radical hysterectomy. Medication was administered postoperatively during 30 days. At the end of this period, urodynamic evaluation was repeated. There was an increase in both the maximum cystometric capacity and bladder capacity at first desire to void in the placebo group compared to the other groups. The rate of detrusor instability was higher in the group that used bethanechol combined with cisapride. Detrusor pressure at maximum flow was significantly higher when cisapride was used. There was a significant increase in postvoid residual volume in the placebo group. In patients undergoing radical hysterectomy, bethanechol and cisapride determined lower cystometric capacity and decreased bladder capacity at first desire to void, a higher maximum flow rate and higher detrusor pressure at maximum flow, with lower postvoid residual volumes. The early use of bethanechol and cisapride after radical hysterectomies positively modified urodynamic parameters, determining a more efficient detrusor function.
Madeiro
Alberto P
AP
São Marcos Hospital, Piauí Cancer Society, Av. Cel. Costa Araújo, 3033, Horto Florestal, Teresina, Piauí, 64049 460, Brazil. madeiro@uol.com.br
Rufino
Andréa C
AC
Sartori
Marair G F
MG
Baracat
Edmund C
EC
Lima
Geraldo Rodrigues De
GR
Girão
Manoel J B C
MJ
D000328:Adult; D000368:Aged; D018723:Bethanechol / Q000627:therapeutic use*; D020117:Cisapride / Q000627:therapeutic use*; D004311:Double-Blind Method; D005260:Female; D005765:Gastrointestinal Agents / Q000627:therapeutic use*; D006801:Humans; D007044:Hysterectomy / Q000379:methods*; D008365:Manometry; D008875:Middle Aged; D018721:Muscarinic Agonists / Q000627:therapeutic use*; D010919:Placebos; D011312:Pressure; D012212:Rheology; D014521:Urethra / Q000187:drug effects / Q000503:physiopathology; D001743:Urinary Bladder / Q000187:drug effects / Q000503:physiopathology; D014554:Urination / Q000187:drug effects / Q000502:physiology; D014556:Urine; D014563:Urodynamics / Q000187:drug effects* / Q000502:physiology; D002583:Uterine Cervical Neoplasms / Q000601:surgery*
D005765:Gastrointestinal Agents; D018721:Muscarinic Agonists; D010919:Placebos; D018723:Bethanechol; D020117:Cisapride